23andMe cuts 40% of its workforce and discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. “We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,
23andMe to Cut 40% of Its Staff Amid Grim Financials
The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on using customers’ DNA data to aid in drug discovery.
23andMe cuts 40 percent of staff amid major business overhaul
In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a staggering 40 percent of
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
23andMe lays off 40% of its workforce, ends therapeutics division
Me is laying off 40 per cent of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe to lay off 40% of its workforce as stock price plummets
The genetic testing company 23andMe is cutting 40% of its workforce and ending its therapeutics program as its stock price continues to plummet. CBS News correspondent Carter Evans has more on what this means for its customers.
Hosted on MSN1d
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...
Business 2 Community22d
Anne Wojcicki Net Worth: 23andMe Stock Price Woes Leaves a $200 Million Fortune
American businesswoman Anne Wojcicki is the co-founder and CEO of genetic testing company 23andMe. She became a billionaire after the company went public in 2021 but since then, the company’s ...
The Financial Times29d
Founder Anne Wojcicki races to rescue 23andMe
That request epitomises the fall of a company that transformed its chief executive and founder Anne Wojcicki, ex-wife of Google founder Sergey Brin, into a paper billionaire when it floated three ...
Yahoo Finance27d
Behind the scenes at 23andMe, questions about a star CEO
Anne Wojcicki, CEO of 23andMe, the struggling DNA testing company, doesn’t think this is the right time to examine her leadership style. “What will be most interesting is writing the story in ...
Black Enterprise1d
23andMe Lays Off 40% Of Employees As Company Undergoes Restructuring
Regarding its workforce reduction, which will total 200 employees, CEO Anne Wojcicki called the layoffs a “difficult but necessary” step to keep the company alive. “We are taking these difficult ...